Related Experiment Video
Updated: May 17, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
[Peptide imaging: the somatostatine model]
Maria Rosaria Prisco1, Andrea Vaccaro, Gianluca Gatta
1Seconda Universita Napoli, Napoli. mariarosaria.prisco@hotmail.it
Abstract:
Radiolabeled cell-surface peptide receptor-binding molecules are emerging as an important class of radiopharmaceuticals. Main approach has been the use of 111In Octreotide as functional imaging to find NETs. In some tumor types, it is considered the diagnostic gold standard. This article focuses on the current status of peptide-receptor scintigraphy in different tumors, in other oncologic and non oncologic applications and on future developments in these fields.
Insights
Radiolabeled peptide receptor-binding molecules are key radiopharmaceuticals for imaging neuroendocrine tumors (NETs). 111In Octreotide is a diagnostic gold standard, with peptide-receptor scintigraphy showing promise in various applications.
Area of Science:
- Radiopharmaceuticals
- Molecular Imaging
- Oncology
Background:
- Radiolabeled cell-surface peptide receptor-binding molecules represent a significant advancement in radiopharmaceutical development.
- 111In Octreotide has been a primary tool for functional imaging of neuroendocrine tumors (NETs).
- In certain tumor types, this approach is considered the diagnostic gold standard.
Purpose of the Study:
- To review the current status of peptide-receptor scintigraphy in various tumor types.
- To explore oncologic and non-oncologic applications of this imaging modality.
- To discuss future developments in the field of peptide-receptor scintigraphy.
Main Methods:
- Review of current literature on peptide-receptor scintigraphy.
- Analysis of diagnostic performance in different tumor types.
- Evaluation of emerging and potential applications.
Main Results:
- Peptide-receptor scintigraphy, particularly with 111In Octreotide, is a valuable diagnostic tool for NETs.
- Its utility extends beyond NETs to other oncologic and non-oncologic conditions.
- Ongoing research is expanding the scope and applications of these radiopharmaceuticals.
Conclusions:
- Peptide-receptor scintigraphy is a well-established and evolving field in nuclear medicine.
- Its role in diagnosing and managing various diseases is significant and growing.
- Future developments promise enhanced diagnostic capabilities and therapeutic applications.
Related Concept Videos
Somatosensation
Peptide Identification Using Tandem Mass Spectrometry
This technique helps gather information regarding the protein from which the peptide was obtained and to study the peptides’ amino acid sequence. Identifying peptides from a complex mixture is an important component of the growing field of...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET

